Brief: Onxeo FY Recurring Operating Loss Narrows To EUR 19.2‍​ Million

Valerio Therapeutics SA

29/03/2018 17:10

March 29 (Reuters) - ONXEO SA  C4X.PA :
    * FY REVENUE EUR ‍​9.5 MILLION VERSUS EUR 4.4 MILLION YEAR
AGO
    * FY RECURRING OPERATING LOSS EUR 19.2‍​ MILLION VERSUS LOSS
OF
EUR 23.2 MILLION YEAR AGO
    * FY NET LOSS EUR 59.1‍​ MILLION VERSUS LOSS OF EUR 22.7
MILLION
YEAR AGO
    * END-DEC. CASH POSITION OF EUR 14.3 MILLION, COVERING
CURRENT
PROGRAMME UNTIL MID-2019
    * LAUNCH OF PRECLINICAL STUDIES WITH FIRST MOLECULE
GENERATED BY
PLATON EXPECTED BEFORE END-2018
    * RESULTS OF STUDY ON COMBINATION OF BELINOSTAT AND ASIDNA
TO BE
PRESENTED AT 2018 AACR CONGRESS
    * RESULTS OF SECOND PHASE I CLINICAL STUDY WITH ASIDNA,
DRIIV,
EXPECTED BEFORE YEAR-END
    * SAYS MIGHT BE ABLE TO LAUNCH CLINICAL TRIAL WITH
BELINOSTAT AND
ASIDNA COMBINATION IN 2018

Source text: https://bit.ly/2GWPAfS
Further company coverage:  C4X.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))